Skip to main content
. 2008 Dec;4(6):1315–1325. doi: 10.2147/vhrm.s4073

Figure 1.

Figure 1

Relationship between odds ratios for cardiovascular events and corresponding differences in systolic blood pressure. Reprinted with permission from Staessen JA, Wang JG, Thijs L. 2003. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens, 21:1055–76. Copyright © 2003 Lippincott Williams & Wilkins. The left-hand panel shows the relationship between odds ratios for cardiovascular events (experimental treatment versus reference treatment) and differences between treatments in achieved systolic blood pressure using data from clinical trials of antihypertensive drugs. The meta-regression line, which is shown with its 95% confidence interval, was weighted for the inverse of the variance of the individual odds ratios. The right-hand panel shows the results of more recent trials superimposed on the meta-regression line.

Abbreviations: AASK, the African American Study of Kidney disease and hypertension; ABCD/NT, Appropriate Blood Pressure Control in Diabetes trial – tight versus usual blood pressure control in normotensive patients; ALLHAT, Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial; ALLHAT/Aml, Antihypertensive and Lipid- Lowering treatment to prevent Heart Attack Trial – amlodipine versus chlorthalidone; ALLHAT/Lis, Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial – lisinopril versus chlorthalidone; ANBP2, Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly; ATMH, Australian Trial in Mild Hypertension; CAPPP, CAptopril Prevention Project; CONVINCE, Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints Trial; DIABHYCAR, the non-insulin-dependent DIAbetes, HYpertension, microalbuminuria or proteinuria, Cardiovascular events, and ramipril study; ELSA, European Lacidipine Study on Atherosclerosis; EWPHE, trial conducted by the European Working Party on High blood pressure in the Elderly; HEP, trial of Hypertension in Elderly Patients in primary care; HOPE, Heart Outcomes Prevention Evaluation study; HOT/LH, Hypertension Optimal Treatment trial – 80 versus 90 mmHg as target diastolic pressure; HOT/MH, Hypertension Optimal Treatment trial – 85 versus 90 mmHg as target diastolic pressure; IDNT2, Irbesartan Diabetic Nephropathy Trial in patients with type-2 diabetes mellitus; INSIGHT, International Nife-dipine GITS Study – Intervention as a Goal for Hypertension Treatment; LIFE/All, Losartan Intervention For Endpoint reduction in hypertension study – all patients; LIFE/DM, Losartan Intervention For Endpoint reduction in hypertension study – diabetic subgroup; MIDAS/NICS/VHAS, combined results of MIDAS, NICS and VHAS; MRC1, Medical Research Council trial of treatment of mild hypertension; MRC2, Medical Research Council trial of treatment of hypertension in older adults; NICOLE, NIsoldipine in Coronary artery disease in LEuven; NORDIL, NOrdic DILtiazem study; PART2, Prevention of Atherosclerosis with Ramipril Trial; PART2/SCAT, combined results of PART2 and SCAT; PATS, Post-stroke Antihypertensive Treatment Study; PREVENT, Prospective Randomized Evaluation of the Vascular Effects Norvasc Trial; PROGRESS/Com, perindopril PROtection aGainst REcurrent Stroke Study – group on combined therapy; PROGRESS/Per, perindopril PROtection aGainst REcurrent Stroke Study – group on single-drug treatment; RENAAL, Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; RCT70–80, combined results of four smaller trials published from 1970 through 1980, including HSCS, OSLO, USPHS, and VACS; SCOPE, Study on COgnition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; STONE, Shanghai Trial of Nifedipine in the Elderly; STOP1, Swedish Trial in Old Patients with hypertension; STOP2/ACEIs, angiotensin-converting enzyme inhibitor arm of STOP2; STOP2/CCBs, calcium-channel blocker arm of STOP2; Syst-China, Systolic hypertension in China trial; Syst-Eur, Systolic hypertension in Europe trial; UKPDS, UKPDS hypertension in diabetes study; UKPDS/CA, UKPDS hypertension in Diabetes Study – captopril versus atenolol; UKPDS/LH, UKPDS hypertension in diabetes study – low versus high on-treatment blood pressure.